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Unravelling the molecular basis of malignancy is a challeng-
ing process of great priority, as cancer rates are increasing
worldwide and because certain cancer types are still incur-
able. The urgent need for novel treatment modalities based
upon recent discoveries at the genetic and epigenetic level
necessitates a strong collaboration between researchers and
clinicians to work toward a common aim: the control of the
carcinogenic process in order to ultimately achieve a 100%
cure rate.
In the last 20 years, a myriad of discoveries at the mo-
lecular level have been accomplished, especially with the
completion of the “Human Genome Project.” This special
issue focuses on how senescence aﬀects tumourigenesis and
how novel senescence-related therapeutic approaches could
be used to beneﬁt tumour regression and eradication eﬀorts.
Mammaliancellshavedevelopedcomplexdefencemech-
anisms, such as apoptosis, growth or cell cycle arrest, and se-
nescence, to combat uncontrolled proliferation caused by
externalstimuli(e.g.,carcinogenicagents).Replicativesenes-
cence occurs when somatic cells spontaneously decline their
growth rate in continuous culture due to an increasing
number of population doublings, eventually terminating in
a quiescent but viable state. Importantly, senescence has
been observed in patients with premalignant tumours but
has not been detected in malignant tumours. Clear evidence
pointstoacrucialroleofcellularsenescenceincounteracting
malignant transformation. Therefore, in order to eradicate
cancer, key molecules (proteins, microRNAs, etc...)a n d
processes important in senescence could be targets for ther-
apeutic intervention.
The papers collected in this issue deal with the above-
mentioned key senescence factors.
(1) All important oncogenes and tumour suppressor
genes crucial in this process are shown. How and
to what extent their targeting would be eﬀective in
cancer therapeutics is reviewed.
(2) Recently, a speciﬁc group of proteins called Sirtu-
ins, which are part of an evolutionarily conserved
family of NAD-dependent protein deacetylases/ADP-
ribosyltransferases, have been identiﬁed as key com-
ponents in senescence and aging. The relationship of
Sirtuins with genomic instability and their inﬂuence
on telomerase and tumourigenesis is discussed.
(3) DNA-damage response and its link with self-renewal
andsenescencearereviewedasdeterminantprocesses
in which senescent cells may decide how their genetic
backgrounds and protein statuses can promote or
prevent carcinogenesis.
(4) MicroRNAs, short noncoding RNA molecules of ∼22
nucleotides, are key post-transcriptional regulators
of gene expression. MicroRNAs have an important
roleintumourdevelopment,progression,chemosen-
sitivity and cellular senescence. Decoding microRNA
function is required for the development of novel2 Journal of Aging Research
therapies, such as restoring tumour suppressor-mic-
roRNAs and targeting onco-microRNAs with anti-
miR technology. All of these approaches are exten-
sively reviewed.
Moreover, abundant evidence suggests that senescence
plays an important role in aging. The paradoxical role of
senescence as a protective mechanism against the eradication
of cancer might be detrimental to the possible contribution
of senescence to aging. The molecular regulation of senes-
cence in cancer and aging is discussed.
Overall, the potential of cellular senescence to be used
as a target for anticancer therapy is a close reality in the
clinical practice. In this issue, therapeutic strategies are fully
considered, and their applications in each case are proposed.
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